RenovoRx RNXT highlights peer-reviewed PK/PD data for TAMP targeting
RenovoRx (RNXT) highlights a peer-reviewed publication presenting pharmacokinetic and pharmacodynamic (PK/PD) data supporting its TAMP™ targeted drug-delivery platform in locally advanced pancreatic cancer.